Clinical Trial Update: Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

Astellas Institute for Regenerative Medicine conducted a Phase 1/2 study evaluating sub-retinal transplantation of MA09-hRPE cells for Stargardt disease, and th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• MA09-hRPE cells

Snippet

Sponsor: Astellas Institute for Regenerative Medicine | Conditions: Stargardt's Macular Dystrophy | Phase 1, Phase 2 | Status: COMPLETED